The biologics revolution is discussed in a June 2010 article by Marc Wortman, titled Peptide Therapeutics Rising Tide.
"Most if not all of Big Pharma and Big Biotech now have rebuilt their internal peptide drug development programs and show interest in start-ups with peptide pipelines and platforms, said Wortman.
The statement by Wortman is demonstrated by the Big Pharma interest in Phylogica's phylomer peptide libraries. The pipeline of deals include negotiations with 20 prospective pharma partners. Ignore for a moment, investor apathy.
Does Phylogica have "the richest source of bioactive peptides with activity against disease targets inside or outside cells" as claimed in their September 2010 presentation. Undoubtedly, we are about to find out.
"We've delivered to Roche what we believe is results there looking for to move to second stage," said director Nick Woolf in an interview to Finance News Network on September 22, 2010. The same day, Woolf purchased 300,000 shares in an on market transaction.
PYC Price at posting:
5.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)